interleukin-2
information and resources from the National Cancer Institute
NCI Thesaurus | interleukin-2
A recombinant analog of endogenous interleukin-2 (IL-2), a cytokine involved in intercellular communication related to cell differentiation, proliferation, inflammation, hematopoiesis, neuronal functions, and release of hormones. IL-2 binds to and activates specific receptors, triggering expression of specific genes, and may induce T cell-mediated tumor regression in some tumor types.NCI Thesaurus | interleukin-2
A recombinant analog of endogenous interleukin-2 (IL-2), a cytokine involved in intercellular communication related to cell differentiation, proliferation, inflammation, hematopoiesis, neuronal functions, and release of hormones. IL-2 binds to and activates specific receptors, triggering expression of specific genes, and may induce T cell-mediated tumor regression in some tumor types.
|
|
|
|
news articles
Role Of Thalidomide And Subcutaneous Interleukin 2 In Metastatic ... Mar 8, 2006
UroToday, ...on phase I/II trials describe the activity of the anti-angiogenic, immunomodulatory agent thalidomide, in combination with subcutaneous interleukin 2 (SCIL-2). ...
EpiCept Announces Publication of Phase III Ceplene(TM) Study ... Mar 30, 2006
Yahoo! News (press release) The Blood article is entitled "Improved Leukemia-Free Survival After Post-Consolidation Immunotherapy with Histamine Dihydrochloride and Interleukin-2 in Acute ...
Hopes Raised for Effectiveness of Multiple Sclerosis Drug Mar 31, 2006
eMaxHealth.com, It was also believed that since activated T-cells need a growth factor called interleukin 2 for their function, drugs that can block the interaction of ...
MS drug has promise, UC team reports Mar 28, 2006
Charlotte Business Journal, The researchers suspected the drug inhibited the interaction of specific white cells (T-cells) and a growth factor called interleukin-2, which can create an ...
Swiss OK for Bayer/Onyx' Nexavar Mar 30, 2006
Pharma Times (subscription), ...three to six months on average, but it also appears to be much less toxic than current treatments for this type of cancer, such as interleukin-2 or interferon ...
Thalidomide and IL-2 Effective for Metastatic Renal Cell Carcinoma Mar 20, 2006
Cancer Consultants (press release), According to an article recently published in the journal Cancer, the treatment combination consisting of thalidomide (Thalomid®) and interleukin-2 (IL-2 ...
International award honors discoveries in cellular and molecular ... Mar 20, 2006
EurekAlert (press release), Interferons interfere with the division of cancer cells and can slow tumor growth; interleukin-2, discovered by Robert Gallo and colleagues, stimulates the ...
Antibody-interleukin Complexes Stimulate Immune Responses, New ... Feb 25, 2006
Medical News Today (press release), The type of monoclonal antibody that was injected was specific to interleukin-2 (IL-2), a naturally occurring protein and a known immunotherapy for metastatic ...
Do 73% of Americans Die from Just One Actual Disease Mar 6, 2006
ClickPress (press release), ...events in the body, resulting in an over production of many pro-inflammatory cytokines, including TNF-a tumor necrosis factor alpha, IL-2 interleukin 2, IL-6 ...
Researchers Discover Molecule Allowing Cancer to Spread Mar 8, 2006
eMaxHealth.com, ...it's possible that patients with low levels of B7-H1 may be the best candidates for immunotherapeutic treatment using agents such as Interleukin-2 (IL-2) and ...
Thalomid® and IL-2 Effective for Metastatic Renal Cell Carcinoma Mar 20, 2006
Cancer Consultants (press release), Researchers from the Methodist Hospital in Houston, Texas, have reported that treatment of metastatic renal cell carcinoma (MRCC) with interleukin-2 (IL-2) and ...
Biomira Inc. announces year-end results Mar 9, 2006
Yahoo! News (press release) This company was created to fully exploit Liposomal Interleukin-2 (L-IL-2) technology that Biomira did not have the resources to fully develop. ...
Drugs trial system 'must be reviewed' Mar 19, 2006
Manchester Evening News, ...system. They include a chemical called interleukin-2, which helps white blood cells to recognise and destroy certain cancer cells. ...
EpiCept Reports 2005 Operating and Financial Results Mar 15, 2006
MSN Money ...the US In 2004, the company reported positive results from a randomized and controlled Phase III trial investigating Ceplene plus IL-2 (interleukin-2) in the ...
Chemotherapy for Immune Disorder Suggested as Avian Flu Treatment Mar 3, 2006
CNN ...and colleagues noted. Both patients had high levels of cytokines, including interleukin-2 and interferon gamma. That finding has ...
Mymetics Announces NIH Plan to Test HIV-AIDS Vaccine Candidate in ... Mar 10, 2006
International News Service, ...is a fundamental though subtle three-dimensional mimicry between the viral envelope glycoprotein gp41 of HIV-1 and the IL-2 cytokine (Interleukin-2) of the ...
Mesothelioma Treatment 101 Mar 2, 2006
Only Idol, Mesothelioma cells proved susceptible to in vitro lysis by LAK cells following activation by interleukin-2 (IL-2), but patients undergoing this particular ...
Patients vs. Paternalism Mar 6, 2006
TCS Daily, A more recent example is aldesleukin (also known as interleukin-2, or IL-2), a drug that has offered new hope to victims of kidney cancer and malignant melanoma ...
Is there any role for thalidomide as a monotherapy in the ... Mar 8, 2006
News-Medical.net, The jury remains out on combinatorial therapy with thalidomide and other agents such as interleukin 2. By Christopher G. Wood, MD.
Clinical Data Evaluating CC-10004 As New Oral Therapy in Severe ... Mar 6, 2006
International News Service, ...molecule with anti- inflammatory activities that inhibits the production of multiple proinflammatory mediators including PDE-4, TNF-alpha, interleukin-2 (IL-2 ...
Activity Of Imatinib (Gleevec®) In Metastatic Renal Cell ... Mar 6, 2006
UroToday, CA (UroToday.com) - Until recently, standard therapy for metastatic renal cell carcinoma (RCC) has been immunotherapy with either interleukin 2 or interferon. ...
Celgene's psoriasis therapy beats expectations in phase II Mar 7, 2006
Pharmaceutical Business Review ...molecule with anti-inflammatory activities that inhibits the production of multiple proinflammatory mediators including PDE-4, TNF-alpha, interleukin-2 (IL-2 ...
Is There Any Role For Thalidomide As A Monotherapy In The ... Mar 7, 2006
UroToday, ...and should be abandoned. The jury remains out on combinatorial therapy with thalidomide and other agents such as interleukin 2.
Etoposide-Based Therapy May Reduce Mortality From Bird Flu Mar 1, 2006
Medscape (subscription) ...or hypofibrinogenemia (or both), hemophagocytosis, ferritin > 500 g/L, low natural killer cell activity, and soluble interleukin-2 receptor > 2400 U/mL. ...
Flamel Technologies Announces Fourth Quarter and Year-End Results Mar 7, 2006
Genetic Engineering News, ...and development expenses concerning the formulation of additional drugs using our technologies, particularly Interferon-alpha and Interleukin-2, as well as a ...
Flamel feels fallout from lost partners Mar 15, 2006
In-PharmaTechnologist.com, ...believes the company can find partners to pick up Basulin and Genvir, as well as other of its advanced products, like its second-generation interleukin-2 and a ...
Stockholders of Maxim Pharmaceuticals Approve Merger Proposal 21 Dec 2005
Black Enterprise, Maxim has completed one Phase 3 clinical trial of Ceplene(TM) plus Interleukin-2 combination therapy as a remission maintenance therapy for patients with acute ...
Stockholders of Maxim Pharmaceuticals Approve Merger Proposal 21 Dec 2005
Finanzen.net, Maxim has completed one Phase 3clinical trial of Ceplene(TM) plus Interleukin-2 combination therapyas a remission maintenance therapy for patients with acute ...
Interleukin-2 has short-lived negative impact on quality of life Dec 1, 2005
Aidsmap, HIV-positive patients taking interleukin-2 (Proleukin) alongside antiretroviral therapy experience problems that reduce their quality of life, according to the ...
Zenotech to launch two bio generics in Feb, plans GDR Dec 20, 2005
Newindpress, The company is planning to launch another bio generic for oncology, Interleukin-2 (IL-2) in the third quarter of the next financial year. ...
New Data Suggest Novel Low-dose Outpatient Chemobiotherapy Regimen ... Dec 12, 2005
PR Newswire (press release), ...of temozolomide, the granulocyte macrophage colony stimulating factor (GM-CSF) LEUKINE(R) (sargramostim), Interferon-alpha-2b and interleukin-2 appears to be ...
Active Biotech Reports Interim Results of ANYARA Phase I Clinical ... Dec 14, 2005
Market Wire (press release) ...generated. These include a sustained level of the immunostimulatory cytokine Interleukin 2 (IL-2) after the second day of treatment. ...
Transgene: Clinical Pipeline Update Nov 29, 2005
PR Newswire (press release), ...sequence and has the potential to generate an immune response to all antigenic epitopes of MUC1; - The sequence coding for the cytokine Interleukin 2 (IL2) is ...
(Euronext Paris) - Transgene : Clinical Pipeline Update Nov 29, 2005
Euronext, 2006. · The sequence coding for the cytokine Interleukin 2 (IL2) is included to help stimulate specific T-cell response. Final ...
UW Medical Center opens Melanoma Center to provide advanced ... Nov 30, 2005
uwnews.org, Among other treatments offered, the Melanoma Center uses the drugs interferon and interleukin-2 to mobilize the body's immune system to fight advanced melanoma ...
Fatigue And Hypothyroidism Dec 6, 2005
Hollister Free Lance, ...medication lithium; interferon alpha, which is used to treat hepatitis C and certain types of leukemia and other cancers; and the cancer drug interleukin-2. ...
The lowdown on thyroid slowdown Dec 11, 2005
ITP.net, ...lithium; interferon alpha, which is used to treat hepatitis C and certain types of leukemia and other cancers; and the cancer drug interleukin-2. Drugs taken ...
DGAP-Ad hoc: PlasmaSelect AG <DE0005471809>: Ad hoc announcement ... Nov 22, 2005
Vereinigte Wirtschaftsdienste, ...those products already marketed by SSP in China and some other Asian countries, which are Erythropoietin, Interferon alpha 2A and Interleukin 2 and furthermore ...
2nd Phase II Trial with Trovax® in Renal Cell Carcinoma, Oxford ... Nov 19, 2005
Medical News Today (press release), Oxford BioMedica announced today that the first patient has been treated in a second Phase II trial with TroVax in combination with interleukin-2 (IL-2) in ...
Sunitinib Promising for Metastatic Renal Cell Carcinoma Nov 18, 2005
Cancer Consultants (press release), ...for metastatic RCC include palliative (non-curative) surgery, radiation therapy, and immune stimulating agents such as Proleukin® (interleukin-2). In an ...
|
|
